%0 Journal Article
%T Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective
%A Kenneth LaPensee
%A Rohit Mistry
%A Thomas Lodise
%J Archive of "American Health & Drug Benefits".
%D 2019
%X Community-acquired bacterial pneumonia (CABP) is an acute, lower respiratory bacterial infection. Despite advances in medical care, CABP remains associated with considerable morbidity, mortality, and healthcare costs; early empiric treatment is recommended by the Infectious Diseases Society of America and by the American Thoracic Society. Omadacycline is an oral and intravenous (IV) once-daily aminomethylcycline antibiotic that is approved in the United States for the treatment of adult patients with CABP
%K bacterial pneumonia
%K budgetary impact
%K community-acquired bacterial pneumonia
%K economic model
%K omadacycline
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442092/